Emerging Importance of Residual Renal Function in End-Stage Renal Failure

Seminars in Dialysis

Volumn 24, Issue 5, 2011, Pages 487-494

  Vilar, Enric ^a   Farrington, Ken ^a  

^a LISTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY FAILURE; EDITORIAL; HUMAN; KIDNEY FUNCTION TEST; METHODOLOGY; MORTALITY; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; SURVIVAL RATE;

HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; RENAL DIALYSIS; SURVIVAL RATE;

EID: 80054697062     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00968.x     Document Type: Editorial

References (122)

1. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE: Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11:556-564, 2000
2. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51:1908-1919, 1997
3. Hidaka H, Nakao T: Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis. Nephrology 8:184-191, 2003
4. Jansen MAM, Hart AAM, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT: Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 62:1046-1053, 2002
5. Rottembourg J, Issad B, Gallego JL, Degoulet P, Aime F, Gueffaf B, Legrain M: Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 19:397-403, 1983
6. Lysaght MJ, Vonesh EF, Gotch F, Ibels L, Keen M, Lindholm B, Nolph KD, Pollock CA, Prowant B, Farrell PC: The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 37:598-604, 1991
7. Misra M, Vonesh E, Van Stone JC, Moore HL, Prowant B, Nolph KD: Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int 59:754-763, 2001
8. Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K: Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant 24:2502-2510, 2009
9. Suda T, Hiroshige K, Ohta T, Watanabe Y, Iwamoto M, Kanegae K, Ohtani A, Nakashima Y: The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant 15:396-401, 2000
10. Swan SK, Halstenson CE, Kasiske BL, Collins AJ: Determination of residual renal function with iohexol clearance in hemodialysis patients. Kidney Int 49:232-235, 1996
11. Sacamay TE, Bolton WK: Use of iohexol to quantify hemodialysis delivered and residual renal function: technical note. Kidney Int 54:986-991, 1998
12. Sterner G, Frennby B, Mansson S, Ohlsson A, Prutz KG, Almen T: Assessing residual renal function and efficiency of hemodialysis-an application for urographic contrast media. Nephron 85:324-333, 2000
13. Miller BF, Alving AS, Rubin J: The renal excretion of inulin at low plasma concentrations of this compound, and its relationship to the glomerular filtration rate in normal, nephritic and hypertensive individuals. J Clin Invest 19:89-94, 1940
14. Sigman EM, Elwood CM, Knox F: The measurement of glomerular filtration rate in man with sodium iothalamate 131-I (Conray). J Nucl Med 7:60-68, 1966
15. Chantler C, Garnett ES, Parsons V, Veall N: Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci 37:169-180, 1969
16. van Olden RW, Krediet RT, Struijk DG, Arisz L: Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 7:745-750, 1996
17. Caravaca F, Arrobas M, Pizarro JL, Sanchez-Casado E: Uraemic symptoms, nutritional status and renal function in pre-dialysis end-stage renal failure patients. Nephrol Dial Transplant 16:776-782, 2001
18. Hilbrands LB, Artz MA, Wetzels JF, Koene RA: Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int 40:1171-1176, 1991
19. van Acker BA, Koomen GC, Koopman MG, de Waart DR, Arisz L: Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 340:1326-1329, 1992
20. van Olden RW, van Acker BA, Koomen GC, Krediet RT, Arisz L: Time course of inulin and creatinine clearance in the interval between two haemodialysis treatments. Nephrol Dial Transplant 10:2274-2280, 1995
21. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association: Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 17(Suppl 7):7-15, 2002
22. Peritoneal Dialysis Adequacy Work Group: NKF-K/DOQI Clinical Practice Guidelines for peritoneal dialysis adequacy: update 2006. Am J Kidney Dis 48(Suppl 1):S98-S129, 2006
23. Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40:221-226, 2002
24. Simonsen O, Grubb A, Thysell H: The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 45:97-101, 1985
25. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP: Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 47:312-318, 1995
26. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD 3rd, Zhang YL, Greene T, Levey AS: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3, 418 individuals with CKD. Am J Kidney Dis 51:395-406, 2008
27. Yang Q, Li R, Zhong Z, Mao H, Fan J, Lin J, Yang X, Wang X, Li Z, Yu X: Is cystatin C a better marker than creatinine for evaluating residual renal function in patients on continuous ambulatory peritoneal dialysis? Nephrol Dial Transplant 2011 Mar 2 [Epub ahead of print]
28. Sjöström PA, Jones IL, Tidman MA: Cystatin C as a filtration marker-haemodialysis patients expose its strengths and limitations. Scand J Clin Lab Invest 69:65-72, 2009
29. Vilar E, Boltiador P, Machado A, Viljoen A, Garrett A, Wellsted D, Farrington K: Removal kinetics of cystatin C during high-flux haemodialysis and haemodiafiltration (Abstract). British Renal Society/Renal Association Conference, Birmingham, 2011
30. Gotch FA: Kinetic modelling in hemodialysis. In: Nissenson AR, Fine RN, Gentile DE (eds). Clinical Dialysis, 3rd edn. Norwalk, CT: Appleton & Lange, 1995:156-188
31. Depner TA: Refinements and application of urea modelling. In: Depner TA (ed.). Prescribing Hemodialysis: A Guide to Urea Modeling. Boston: Kluwer, 1991:168-194
32. Casino FG, Lopez T: The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant 11:1574-1581, 1996
33. Gotch FA: The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 13(Suppl 6):10-14, 1998
34. Daugirdas JT, Depner TA, Greene T, Silisteanu P: Solute-solver: a web-based tool for modeling urea kinetics for a broad range of hemodialysis schedules in multiple patients. Am J Kidney Dis 54:798-809, 2009
35. Gao H, Lew SQ, Ronco C, Mishkin GJ, Bosch JP: The impact of residual renal function and total body water volume on achieving adequate dialysis in CAPD. J Nephrol 12:184-189, 1999
36. Tattersall JE, Doyle S, Greenwood RN, Farrington K: Kinetic modelling and underdialysis in CAPD patients. Nephrol Dial Transplant 8:535-538, 1993
37. Burkart JM, Satko SG: Incremental initiation of dialysis: one center's experience over a two-year period. Perit Dial Int 20:418-422, 2000
38. Caravaca F, Arrobas M, Dominguez C: Influence of residual renal function on dietary protein and caloric intake in patients on incremental peritoneal dialysis. Perit Dial Int 19:350-356, 1999
39. Nolph KD: Rationale for early incremental dialysis with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 13(Suppl 6):117-119, 1998
40. Maiorca R, Brunori G, Zubani R, Cancarini GC, Manili L, Camerini C, Movilli E, Pola A, d'Avolio G, Gelatti U: Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant 10:2295-2305, 1995
41. Szeto CC, Wong TY, Leung CB, Wang AY, Law MC, Lui SF, Li PK: Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int 58:400-407, 2000
42. Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang SM, Zhu X, Lazarus JM: Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis 33:523-534, 1999
43. Canada -USA (CANUSA) Peritoneal Dialysis Study Group: Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 7:198-207, 1996
44. Bargman JM, Thorpe KE, Churchill DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 12:2158-2162, 2001
45. Wang AY, Wang M, Woo J, Law MC, Chow KM, Li PK, Lui SF, Sanderson JE: A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 62:639-647, 2002
46. Lopez-Menchero R, Miguel A, Garcia-Ramon R, Perez-Contreras J, Girbes V: Importance of residual renal function in continuous ambulatory peritoneal dialysis: its influence on different parameters of renal replacement treatment. Nephron 83:219-225, 1999
47. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG: Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 16:2207-2213, 2001
48. Van Biesen W, Vanholder R, Veys N, Lameire N: Peritoneal dialysis in anuric patients: concerns and cautions. Semin Dial 15:305-310, 2002
49. Perez-Flores I, Coronel F, Cigarran S, Herrero JA, Calvo N: Relationship between residual renal function, inflammation, and anemia in peritoneal dialysis. Adv Perit Dial 23:140-143, 2007
50. Wang AY, Sea MM, Ip R, Law MC, Chow KM, Lui SF, Li PK, Woo J: Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 12:2450-2457, 2001
51. Wang AY, Woo J, Wang M, Sea MM, Sanderson JE, Lui SF, Li PK: Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 20:396-403, 2005
52. Penne EL, van der Weerd NC, Grooteman MP, Mazairac AH, van den Dorpel MA, Nube MJ, Bots ML, Levesque R, ter Wee PM, Blankestijn PJ: Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol 6:281-289, 2011
53. Shemin D, Bostom AG, Laliberty P, Dworkin LD: Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38:85-90, 2001
54. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT: The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 41:1293-1302, 2003
55. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT: Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 15:1061-1070, 2004
56. Korevaar JC, Jansen MA, Dekker FW, Jager KJ, Boeschoten EW, Krediet RT, Bossuyt PM: When to initiate dialysis: effect of proposed US guidelines on survival. Lancet 358:1046-1050, 2001
57. Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, Harris A, Johnson DW, Kesselhut J, Li JJ, Luxton G, Pilmore A, Tiller DJ, Harris DC, Pollock CA: A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363:609-619, 2010
58. Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG: Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol 13:2125-2132, 2002
59. Perl J, Bargman JM: The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis 53:1068-1081, 2009
60. Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT: Quality of life in patients on chronic dialysis: self-assessment 3months after the start of treatment. The Necosad Study Group. Am J Kidney Dis 29:584-592, 1997
61. Babb AL, Ahmad S, Bergstrom J, Scribner BH: The middle molecule hypothesis in perspective. Am J Kidney Dis 1:46-50, 1981
62. Bargman JM, Golper TA: The importance of residual renal function for patients on dialysis. Nephrol Dial Transplant 20:671-673, 2005
63. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 64:2238-2243, 2003
64. Montini G, Amici G, Milan S, Mussap M, Naturale M, Ratsch IM, Ammenti A, Sorino P, Verrina E, Andreetta B, Zacchello G: Middle molecule and small protein removal in children on peritoneal dialysis. Kidney Int 61:1153-1159, 2002
65. Blumberg A, Burgi W: Behavior of beta 2-microglobulin in patients with chronic renal failure undergoing hemodialysis, hemodiafiltration and continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 27:245-249, 1987
66. Amici G, Virga G, Da Rin G, Grandesso S, Vianello A, Gatti P, Bocci C: Serum beta-2-microglobulin level and residual renal function in peritoneal dialysis. Nephron 65:469-471, 1993
67. Mistry CD, O'Donoghue DJ, Nelson S, Gokal R, Ballardie FW: Kinetic and clinical studies of beta 2-microglobulin in continuous ambulatory peritoneal dialysis: influence of renal and enhanced peritoneal clearances using glucose polymer. Nephrol Dial Transplant 5:513-519, 1990
68. Fry AC, Singh DK, Chandna SM, Farrington K: Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif 25:295-302, 2007
69. Gorevic PD, Munoz PC, Casey TT, DiRaimondo CR, Stone WJ, Prelli FC, Rodrigues MM, Poulik MD, Frangione B: Polymerization of intact beta 2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis. Proc Natl Acad Sci USA 83:7908-7912, 1986
70. Shirahama T, Skinner M, Cohen AS, Gejyo F, Arakawa M, Suzuki M, Hirasawa Y: Histochemical and immunohistochemical characterization of amyloid associated with chronic hemodialysis as beta 2-microglobulin. Lab Invest 53:705-709, 1985
71. Copley JB, Lindberg JS: Nontransplant therapy for dialysis-related amyloidosis. Semin Dial 14:94-98, 2001
72. Konings CJ, Kooman JP, Schonck M, Struijk DG, Gladziwa U, Hoorntje SJ, van der Wall Bake AW, van der Sande FM, Leunissen KM: Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant 18:797-803, 2003
73. Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM, Akiba T, Kurokawa K, Ramirez S, Young EW: Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 49:426-431, 2007
74. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1995
75. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, Sanderson JE: Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 15:2186-2194, 2004
76. Wang AY, Woo J, Sea MM, Law MC, Lui SF, Li PK: Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications? Am J Kidney Dis 43:712-720, 2004
77. Morduchowicz G, Winkler J, Zabludowski JR, Boner G: Effects of residual renal function in haemodialysis patients. Int Urol Nephrol 26:125-131, 1994
78. Wang AY, Lai KN: The importance of residual renal function in dialysis patients. Kidney Int 69:1726-1732, 2006
79. Szeto CC, Lai KN, Wong TY, Law MC, Leung CB, Yu AW, Li PK: Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcome in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 34:1056-1064, 1999
80. Bemelmans MH, Gouma DJ, Buurman WA: Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 150:2007-2017, 1993
81. Aminzadeh MA, Pahl MV, Barton CH, Doctor NS, Vaziri ND: Human uraemic plasma stimulates release of leptin and uptake of tumour necrosis factor-alpha in visceral adipocytes. Nephrol Dial Transplant 24:3626-3631, 2009
82. Cancarini GC, Brunori G, Camerini C, Brasa S, Manili L, Maiorca R: Renal function recovery and maintenance of residual diuresis in CAPD and hemodialysis. Perit Dial Int 6:77-79, 1986
83. Rottembourg J, Issad B, Allouache M, Jacobs C: Recovery of renal function in patients treated by CAPD. Adv Perit Dial 5:63-66, 1989
84. Michel C, Haddoum F, Viron B, Mignon F: [Recovery of renal function after treatment with continuous ambulatory peritoneal dialysis]. Nephrologie 10(Suppl):53-55, 1989
85. Wang T, Ye RG, Zhen ZH, Li HQ, Mai WY: Influence of peritoneal dialysis on the progression of chronic renal failure. Adv Perit Dial 11:139-141, 1995
86. McKane W, Chandna SM, Tattersall JE, Greenwood RN, Farrington K: Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 61:256-265, 2002
87. Macdonald JA, McDonald SP, Hawley CM, Rosman J, Brown F, Wiggins KJ, Bannister K, Johnson DW: Recovery of renal function in end-stage renal failure-comparison between peritoneal dialysis and haemodialysis. Nephrol Dial Transplant 24:2825-2831, 2009
88. Hiroshige K, Yuu K, Soejima M, Takasugi M, Kuroiwa A: Rapid decline of residual renal function in patients on automated peritoneal dialysis. Perit Dial Int 16:307-315, 1996
89. Hufnagel G, Michel C, Queffeulou G, Skhiri H, Damieri H, Mignon F: The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 14:1224-1228, 1999
90. Rodriguez AM, Diaz NV, Cubillo LP, Plana JT, Riscos MA, Delgado RM, Herrera CM, Ribes EA, Molina FT, Heras MM, Gonzalez AT, Canton CG, Fernandez AR, Laborda EB, Zurita MN, Giron FF, Santana PS: Automated peritoneal dialysis: a Spanish multicentre study. Nephrol Dial Transplant 13:2335-2340, 1998
91. Bro S, Bjorner JB, Tofte-Jensen P, Klem S, Almtoft B, Danielsen H, Meincke M, Friedberg M, Feldt-Rasmussen B: A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int 19:526-533, 1999
92. de Fijter CW, ter Wee PM, Donker AJ: The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 15:1094-1096, 2000
93. Shemin D, Maaz D, St Pierre D, Kahn SI, Chazan JA: Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 34:14-20, 1999
94. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG: Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 20:429-438, 2000
95. Van Stone JC: The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO J 41:M713-M716, 1995
96. McCarthy JT, Jenson BM, Squillace DP, Williams AW: Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. Am J Kidney Dis 29:576-583, 1997
97. Hartmann J, Fricke H, Schiffl H: Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 30:366-373, 1997
98. Caramelo C, Alcazar R, Gallar P, Teruel JL, Velo M, Ortega O, Galera A, Da Silva M: Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant 9:675-677, 1994
99. Hakim RM: Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 44:484-494, 1993
100. Pertosa G, Grandaliano G, Gesualdo L, Schena FP: Clinical relevance of cytokine production in hemodialysis. Kidney Int Suppl 76:S104-S111, 2000
101. Smeby LC, Wideroe TE, Balstad T, Jorstad S: Biocompatibility aspects of cellophane, cellulose acetate, polyacrylonitrile, polysulfone and polycarbonate hemodialyzers. Blood Purif 4:93-101, 1986
102. Stannat S, Bahlmann J, Kiessling D, Koch KM, Deicher H, Peter HH: Complement activation during hemodialysis. Comparison of polysulfone and cuprophan membranes. Contrib Nephrol 46:102-108, 1985
103. Schiffl H, Lang SM, Fischer R: Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 17:1814-1818, 2002
104. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66:408-418, 2004
105. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM: Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 73:200-206, 2008
106. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, Gerlag PG, Hoorntje SJ, Wolters J, van der Sande FM, Leunissen KM: Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 63:1556-1563, 2003
107. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimburger O, Simonsen O, Davenport A, Tranaeus A, Divino Filho JC: Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 14:2338-2344, 2003
108. Davies SJ: Exploring new evidence of the clinical benefits of icodextrin solutions. Nephrol Dial Transplant 21(Suppl 2):ii47-ii50, 2006
109. Davies SJ: Preserving residual renal function in peritoneal dialysis: volume or biocompatibility? Nephrol Dial Transplant 24:2620-2622, 2009
110. Medcalf JF, Harris KP, Walls J: Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 59:1128-1133, 2001
111. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC: Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 139:105-112, 2003
112. Fang W, Oreopoulos DG, Bargman JM: Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 23:3704-3710, 2008
113. Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA: Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 115:513-519, 1991
114. Kolesnyk I, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT: Treatment with angiotensin II inhibitors and residual renal function in peritoneal dialysis patients. Perit Dial Int 31:53-59, 2000
115. DuBose TD: Nephrotoxicity of non-steroidal anti-inflammatory drugs. Lancet 344:515-518, 1994
116. Gambaro G, Perazella MA: Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 253:643-652, 2003
117. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, Farid N, McManamon PJ: Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320:143-149, 1989
118. Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 89:615-620, 1990
119. Heinrich MC, Haberle L, Muller V, Bautz W, Uder M: Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 250:68-86, 2009
120. Schiffl H: Prospective randomized cross-over long-term comparison of online haemodiafiltration and ultrapure high-flux haemodialysis. Eur J Med Res 12:26-33, 2007
121. Vilar E, Fry AC, Wellsted D, Tattersall JE, Greenwood RN, Farrington K: Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. Clin J Am Soc Nephrol 4:1944-1953, 2009
122. Penne EL, van der Weerd NC, Blankestijn PJ, van den Dorpel MA, Grooteman MP, Nube MJ, Ter Wee PM, Levesque R, Bots ML: Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients. Clin J Am Soc Nephrol 5:80-86, 2010